Biotricity, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTCY research report →
Range $4 – $4
Price Chart
About the company
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capabilities to the medical, healthcare, and individual consumer markets, encompassing both diagnostic tools and ongoing management support for chronic and lifestyle-related conditions.
- CEO
- Waqaas Al-Siddiq
- IPO
- 2018
- Employees
- 46
- HQ
- Redwood City, CA, US
AI snapshot
Six angles, distilled from the data.
BTCY is still in a long-term downtrend, trading well below its 200-day average of 0.1447 and far under its 52-week high of 0.575. The stock has staged a sharp rebound from the 52-week low of 0.0409, but the broader regime remains a deep-capital-loss setup rather than a confirmed trend reversal.
Street sentiment is constructive but thin, with a 3.0 consensus and a $4 target that sits far above the current share price. The latest rating action kept the stock at Buy, reinforcing a positive long-term view, but the target has not moved since 2023 and the setup still depends on execution.
The earnings pattern has been favorable, with 5 straight EPS beats in the recent run and the last reported quarter coming in at -0.04 versus -0.11 expected. Next-year estimates point to a smaller loss, with 2026-03-31 EPS seen at -0.32 versus -0.58 in 2025, so shareholders should watch for continued margin discipline and revenue traction.
No notable discretionary insider buying or selling. Recent activity is dominated by award grants to the CEO, CFO, and a director, which reads as compensation rather than a trading signal. That pattern suggests alignment through equity issuance, not open-market conviction.
Profitability is mixed: gross margin is strong at 81.8%, but net margin is still -16.67% and ROE is -41.0%. Revenue growth is positive at 11.5% year over year, yet operating cash flow was -718,955 and cash on hand was only 149,789 against 27.1 million of total debt.
BTCY looks like a small-cap medical device turnaround rather than a mature peer. The valuation is depressed versus the healthcare equipment group, with a sub-$2 million market cap and a negative earnings profile that keeps the story tied to execution, not multiple expansion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.18M
- P/E
- -0.39
- PEG
- -0.07
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 75.29
- Div Yield
- 0.00%
- Gross Margin
- 83.25%
- Op Margin
- 7.82%
- Net Margin
- -21.99%
- ROE
- 10.60%
- ROIC
- -5.53%
Latest fiscal year · YoY change
- Revenue
- $16.00M+16.0%
- Gross Profit
- $12.95M+22.6%
- Op Income
- $1.69M
- Net Income
- $-2,404,139+71.5%
- EPS
- $-0.11+80.0%
- OCF Growth
- +69.8%
- FCF Growth
- +69.8%
- 52W High
- $0.57
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.14
- Beta
- 1.22
- RSI (14)
- 52
- Avg Volume
- 57.43K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biotricity reported another quarter of growth and margin expansion, with positive EBITDA for a third straight quarter and management saying it is nearing profitability.· February 11, 2026
- Revenue rose 10.2% year over year to $4.0 million.
- Gross profit increased 17.6% to $3.3 million, and gross margin improved to 81.5% from 76.4%.
- EBITDA was positive for the third consecutive quarter at $280,000, and operating income was positive at $441,000.
- Operating expenses fell 4.2% year over year to $2.8 million, led by lower SG&A.
- Management expects revenue to keep growing and said the company is on track to become net income positive this year.
For the third quarter of fiscal 2026, revenue increased 10.2% year over year to $4.0 million from $3.6 million. Gross profit was $3.3 million, up 17.6% from $2.8 million, and gross margin improved 516 basis points to 81.5% from 76.4%. Operating expenses were $2.8 million versus $2.93 million last year, down 4.2%. EBITDA was $280,000, operating income was $441,000, net loss attributable to common stockholders was $1.1 million versus $1.3 million last year, and loss per share was $0.042 versus $0.054. Management did not give formal next-quarter or full-year numeric guidance, but said revenue should continue to grow, the company expects to turn net income positive this year, and it is pursuing continued margin and expense improvement.
The CEO framed the quarter as another step in Biotricity’s move toward durable recurring growth, citing three straight quarters of positive net operating income and EBITDA. He emphasized demand for remote patient management, the expansion of its cardiac AI cloud platform, international regulatory progress, and growth in Biocore Pro and Bioheart. His tone was confident and upbeat, with repeated comments that the company is setting up for another growth year and expects to shift to profitability in 2026.
The CFO highlighted that revenue was $4.0 million, gross profit was $3.3 million, and gross margin improved to 81.5%, driven by a higher mix of recurring technology fees and lower cloud/monitoring costs. He said technology fees were 91.2% of quarterly revenue, operating expenses declined to $2.8 million, SG&A fell 8.2%, and R&D rose by $72,000. He also noted positive free cash flow for the last 6 consecutive quarters, positive EBITDA of $280,000, and operating profit of $441,000, saying these trends put the company on a path toward profitability.
There was no analyst Q&A on the call, as the operator stated there were no questions. Management therefore did not have to address follow-up concerns about the quarter, guidance, cash needs, or competitive risks. The closest substitute was management’s closing comment that it expects top-line growth and net income positivity this year.
The bull case from this call is that Biotricity is showing both growth and operating leverage: revenue rose, gross margin expanded sharply, and expenses declined. Management also pointed to three straight quarters of positive EBITDA and operating income, plus 6 consecutive quarters of positive free cash flow, suggesting the business is moving closer to sustained profitability.
The main risk is that the company is still not profitable on a net income basis, with a $1.1 million net loss in the quarter. Management offered no formal numeric guidance, so investors are left relying on optimism about pipeline visibility, regulatory approvals, and continued adoption of Biocore Pro rather than on specific targets.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 62.1%
- Shares Outstanding
- 19.91M
- Float Shares
- 12.38M
of shares held by institutions
2 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 13.38K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 23 | Rosa David A | other | 75,930 |
| Mar 12, 23 | Al-Siddiq Waqaas | other | 1,000,000 |
| Mar 12, 23 | Al-Siddiq Waqaas | other | 350,000 |
| Mar 12, 23 | Al-Siddiq Waqaas | other | 350,000 |
| Dec 31, 22 | Ayanoglou John | other | 218,785 |
| Sep 30, 22 | Ayanoglou John | other | 118,282 |
| Jun 30, 22 | Ayanoglou John | other | 53,827 |
| Mar 31, 22 | Ayanoglou John | other | 37,594 |
| Dec 31, 21 | Ayanoglou John | other | 50,000 |
| Sep 30, 21 | Ayanoglou John | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTCY coverage
Recent articles, reports, and earnings notes.
No research on BTCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTCY report →Biotricity Reports Second Quarter Fiscal 2027 Results
globenewswire.com · Nov 20
Biotricity, Inc to Present at the LD Micro Invitational XVI
newsfilecorp.com · May 12
Financial Survey: 10x Genomics (NASDAQ:TXG) and Biotricity (OTCMKTS:BTCY)
defenseworld.net · Feb 20
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Feb 11
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
globenewswire.com · Feb 11
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
globenewswire.com · Feb 5
Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)
defenseworld.net · Jan 12
Head-To-Head Analysis: Zepp Health (NYSE:ZEPP) versus Biotricity (OTCMKTS:BTCY)
defenseworld.net · Dec 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 22, 2026 · Live quote · Not investment advice